<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197677</url>
  </required_header>
  <id_info>
    <org_study_id>Euro CMR</org_study_id>
    <nct_id>NCT01197677</nct_id>
  </id_info>
  <brief_title>European CMR Registry</brief_title>
  <official_title>European Cardiovascular Magnetic Resonance Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiftung Institut fuer Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stiftung Institut fuer Herzinfarktforschung</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The main aim of the first specific protocol initiated by the European CMR registry,
           suspected CAD, is to demonstrate that patients presenting for work up of suspected
           coronary artery disease, which have a completely normal CMR scan will have a low risk
           for cardiovascular events.

        2. The main aim of the second specific protocol initiated by the European CMR registry,
           HCM-SCD, will be to evaluate CMR for risk stratification in hypertrophic
           cardiomyopathy(HCM).

        3. This registry is sought to collect data on the general use of CMR in the European
           clinical practice, its safety and its therapeutic implications in a high number of cases
           to 1) substantiate the clinical yield of CMR and 2) to define additional clinical
           questions worth to be investigated in detail as additional specific protocols in the
           future.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>collect data from a large number of patients regarding the general use of CMR in European clinical practice, its safety and its therapeutic implications</measure>
    <time_frame>01/01/2009-</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to show that a normal CMR protocol (incl. LV wall motion at rest, stress ischemia, and scar detection) predicts a low risk of future cardiovascular events.</measure>
    <time_frame>01/01/2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate if myocardial scarring assessed by contrast-enhanced CMR is a stronger predictor of adverse events during follow up than the general clinical markers of an adverse long term outcome in HCM.</measure>
    <time_frame>01/01/2009-</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30000</enrollment>
  <condition>Consecutive Patients Undergoing CMR</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients undergoing CMR (enrolled into the &quot;European clinical practice&quot;-part of
        the registry Consecutive patients with suspected coronary artery disease or with
        hypertrophic cardiomyopathy (enrolled into the specific protocols &quot;suspected-CAD&quot; or
        &quot;HCM-SCD&quot;).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - European clinical practice: Consecutive patients with accomplished CMR.

        -Suspected-CAD: Consecutive patients with suspected coronary artery disease undergoing a
        combined CMR protocol including evaluation of LV function, assessment of myocardial
        ische¬mia by adenosine stress perfusion or high-dose dobutamine CMR and detection of
        myocardial infarction using contrast-enhanced CMR.

        - HCM-SCD: Consecutive patients with hypertrophic cardiomyopathy undergoing a combined CMR
        protocol including LV function, rest perfusion, and detection of myocardial scarring by
        contrast-enhanced CMR. The diagnosis of hypertrophic cardiomyopathy is based on the
        demonstration of a hypertrophied, non-dilated left ventricle (wall thickness of at least 15
        mm in adults or the equivalent relative to body-surface area in children) in the absence of
        another cardiac or systemic disease capable of producing a similar degree of hypertrophy.
        In adult relatives of the patients with hypertrophic cardiomyo¬pathy, a wall thickness of
        13 mm or more will be considered a criterion for diagnosis.

        Exclusion Criteria:

          -  European clinical practice: None

          -  Suspected-CAD: Missing informed consent. Patients with known CAD by invasive coronary
             angiography or previous MI.

          -  HCM-SCD: Missing informed consent. Patients with known CAD by invasive coronary
             angiography or previous MI. Patients with left ventricular hypertrophy of other causes
             (e.g. hypertension, valvular heart disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heiko Mahrholdt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert-Bosch-Medical-Center, Stuttgart, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver Bruder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elisabeth-Hospital, Essen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Agatharied</name>
      <address>
        <city>Hausham</city>
        <zip>83734</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg-Bietigheim</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Bosch Medical Centre</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Physiology Institute</name>
      <address>
        <city>Pisa</city>
        <zip>56010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Bruder O, Wagner A, Mahrholdt H. Lessons Learned from the European Cardiovascular Magnetic Resonance (EuroCMR) Registry Pilot Phase. Curr Cardiovasc Imaging Rep. 2010 Jun;3(3):171-174. Epub 2010 Apr 13.</citation>
    <PMID>20461126</PMID>
  </reference>
  <reference>
    <citation>Wagner A, Bruder O, Schneider S, Nothnagel D, Buser P, Pons-Lado G, Dill T, Hombach V, Lombardi M, van Rossum AC, Schwitter J, Senges J, Sabin GV, Sechtem U, Mahrholdt H, Nagel E. Current variables, definitions and endpoints of the European cardiovascular magnetic resonance registry. J Cardiovasc Magn Reson. 2009 Nov 5;11:43. doi: 10.1186/1532-429X-11-43.</citation>
    <PMID>19891768</PMID>
  </reference>
  <reference>
    <citation>Bruder O, Schneider S, Nothnagel D, Dill T, Hombach V, Schulz-Menger J, Nagel E, Lombardi M, van Rossum AC, Wagner A, Schwitter J, Senges J, Sabin GV, Sechtem U, Mahrholdt H. EuroCMR (European Cardiovascular Magnetic Resonance) registry: results of the German pilot phase. J Am Coll Cardiol. 2009 Oct 6;54(15):1457-66. doi: 10.1016/j.jacc.2009.07.003. Epub 2009 Aug 13.</citation>
    <PMID>19682818</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMR</keyword>
  <keyword>Register</keyword>
  <keyword>CAD</keyword>
  <keyword>myocard scarring</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

